康希诺生物

Clinical Trail

: Conducted dozens of clinical trials globally and accumulate operating experience

Expertise in registration and regulatory affairs: by 2023, dozens of regulatory approvals have been obtained in Chinese Mainland, Hong Kong, Canada, Hungary, the United Arab Emirates, Ecuador, Mexico, Argentina, Chile, Brazil, Russia, Malaysia, Indonesia, Pakistan, Kyrgyzstan and other places

Manufacturing

The quality management system has obtained GMP certification from both China and the European Union

Compliant with international standards, including regulations and guidelines of WHO/USFDA/EU/NMPA

Commercialization

One-stop vaccine supply and service

Building new speeds and capabilities to accelerate vaccine acquisition and commercial expansion